143 related articles for article (PubMed ID: 31335938)
1. Assessing the lymphoid tissue bioavailability of antiretrovirals in human primary lymphoid endothelial cells and in mice.
Dyavar SR; Gautam N; Podany AT; Winchester LC; Weinhold JA; Mykris TM; Campbell KM; Alnouti Y; Fletcher CV
J Antimicrob Chemother; 2019 Oct; 74(10):2974-2978. PubMed ID: 31335938
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.
DeJesus E; Saleh S; Cheng S; van der Mey D; Becker C; Frey R; Unger S; Mueck W
Pulm Circ; 2019; 9(2):2045894019848644. PubMed ID: 30997864
[TBL] [Abstract][Full Text] [Related]
3. Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
Kosloski MP; Oberoi R; Wang S; Viani RM; Asatryan A; Hu B; Ding B; Qi X; Kim EJ; Mensa F; Kort J; Liu W
J Infect Dis; 2020 Jan; 221(2):223-231. PubMed ID: 31504702
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine.
Khatri A; Dutta S; Dunbar M; Podsadecki T; Trinh R; Awni W; Menon R
Antimicrob Agents Chemother; 2016 May; 60(5):2965-71. PubMed ID: 26953200
[TBL] [Abstract][Full Text] [Related]
5. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
[TBL] [Abstract][Full Text] [Related]
6. Intramuscular and subcutaneous administration of antiretroviral drugs, compared with oral, enhances delivery to lymphoid tissues in BALB/c mice.
Dyavar SR; Kumar S; Gautam N; Podany AT; Winchester LC; Weinhold JA; Mykris TM; Nallasamy P; Alnouti Y; Fletcher CV
J Antimicrob Chemother; 2021 Sep; 76(10):2651-2658. PubMed ID: 34312680
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.
Rimawi BH; Johnson E; Rajakumar A; Tao S; Jiang Y; Gillespie S; Schinazi RF; Mirochnick M; Badell ML; Chakraborty R
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348149
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals.
Begley R; Das M; Zhong L; Ling J; Kearney BP; Custodio JM
J Acquir Immune Defic Syndr; 2018 Aug; 78(4):465-472. PubMed ID: 29649076
[TBL] [Abstract][Full Text] [Related]
9. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Tolerability of Integrase Inhibitors in Antiretroviral-Naive Patients.
D'Abbraccio M; Busto A; De Marco M; Figoni M; Maddaloni A; Abrescia N
AIDS Rev; 2015; 17(3):171-85. PubMed ID: 26450805
[TBL] [Abstract][Full Text] [Related]
11. [Initial antiretroviral therapy in HIV-infected patients].
Cormier H; Hoen B
Rev Prat; 2014 Oct; 64(8):1079-85. PubMed ID: 25510130
[TBL] [Abstract][Full Text] [Related]
12. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
Kabbara WK; Ramadan WH
J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757
[TBL] [Abstract][Full Text] [Related]
13. An Efficient Humanized Mouse Model for Oral Anti-Retroviral Administration.
Virdi AK; Ho S; Seaton MS; Olali AZ; Narasipura SD; Barbian HJ; Olivares LJ; Gonzalez H; Winchester LC; Podany AT; Ross RD; Al-Harthi L; Wallace J
Cells; 2023 Mar; 12(7):. PubMed ID: 37048107
[TBL] [Abstract][Full Text] [Related]
14. Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
Mogalian E; Stamm LM; Osinusi A; Brainard DM; Shen G; Ling KHJ; Mathias A
Clin Infect Dis; 2018 Aug; 67(6):934-940. PubMed ID: 29522076
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester.
Shenkoya B; Atoyebi S; Eniayewu I; Akinloye A; Olagunju A
Front Pediatr; 2021; 9():734122. PubMed ID: 34616699
[TBL] [Abstract][Full Text] [Related]
16. A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models.
Scholz EMB; Cao Y; Kashuba ADM
J Antimicrob Chemother; 2021 Oct; 76(11):2890-2893. PubMed ID: 34374767
[TBL] [Abstract][Full Text] [Related]
17. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Alejos B; Schwimmer C; Bernardino JI; Rodes B; Allavena C; Hoffmann C; Gisslén M; de Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
J Infect Dis; 2018 Oct; 218(10):1523-1530. PubMed ID: 29982509
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs.
Devanathan AS; Pirone JR; Akkina R; Remling-Mulder L; Luciw P; Adamson L; Garcia JV; Kovarova M; White NR; Schauer AP; Blake K; Sykes C; Burgunder EM; Srinivas N; Rosen EP; Kashuba ADM
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611355
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
